What one share of Inmune Bio holds
Bio is a clinical-stage biotechnology company dedicated to developing and commercializing a pipeline of product candidates designed to
Inmune Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.69 |
|---|---|
| Cash and investments | $0.67 |
| Debt | $0.54 |
| Book value | $0.74 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $0.00 | −$0.13 | — | — | — | $2.18 |
| 2018 | $0.00 | −$1.43 | — | — | — | $1.90 |
| 2019 | — | −$0.75 | — | — | — | $2.19 |
| 2020 | $0.00 | −$1.01 | — | — | — | $2.87 |
| 2021 | $0.01 | −$1.88 | — | — | — | $4.50 |
| 2022 | $0.02 | −$1.52 | — | — | — | $3.35 |
| 2023 | $0.01 | −$1.67 | — | — | — | $2.08 |
| 2024 | $0.00 | −$2.11 | — | — | — | $1.44 |
| 2025 | $0.00 | −$1.86 | $0.04 | −$0.95 | — | $0.88 |
Common questions about Inmune Bio
How much does one share of Inmune Bio earn?
Over the last 12 months, Inmune Bio lost $0.69 for each share.
Does Inmune Bio pay a dividend?
Inmune Bio didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Inmune Bio’s book value per share?
Inmune Bio’s book value is $0.74 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Inmune Bio have?
Each share of Inmune Bio has $0.67 of cash and investments and $0.54 of debt, as of June 30, 2026.
Has Inmune Bio bought back shares?
Inmune Bio’s share count rose about 277% from 2017 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.